Post Date: November 11, 2021
“After decades of research in pediatric neurology and psychiatry, it is extremely gratifying to achieve positive and meaningful study results for a patient group that has such a high unmet medical need,” said Lead Investigator Donald Gilbert, MD, MS, Pediatric Movement Disorders and Tourette Syndrome Specialist, Division of Neurology at Cincinnati Children’s. “We are one step closer to a potentially life-changing therapy for a patient group who inspires and fuels our efforts.”
Emalex Biosciences, Inc., announced on Nov. 10, 2021, results from its Phase 2b clinical study (D1AMOND Study) of its drug ecopipam (EBS-101), a dopamine-1 (D1) receptor antagonist, for the treatment of pediatric patients with Tourette syndrome.
The trial included 153 children ages 6 to 18 who participated in a 12-week treatment course at 63 sites across the U.S., Canada and Europe.
“Statistically significant and clinically meaningful results were obtained on this primary endpoint at all timepoints, from Week 4 to Week 12,” the company states.
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.